|
Cancer World Newsletter - Skin toxicities caused by targeted therapies |
 |
 |
 |
Many targeted cancer medicines cause a variety of unpleasant skin problems that patients
can find hard to tolerate, because they are unsightly, itchy and painful. While some of them,
such as rash and paronychia, have been well described, there is much less awareness of
others. This egrandround offers advice on what to look out for, and how to work as a team to
identify different problems, assess which ones the patient finds most bothersome, and take
steps to ameliorate them.
You can read the article here. Press the comment button at the end to share your views.
|
|
|
Cancer World Newsletter - Best Reporter, Tobacco tactics in the headlines |
|
|
|
Cigarette manufacturers survive by exploiting every avenue to ensure each new generation
becomes hooked on their product. But they prefer to operate in secret. This article tells the
story of how Best Cancer Reporter Special Merit Award winner Steve Connor, science
correspondent for the UK's Independent newspaper, made the front page with an exposé of
their tactics.
- Have you read anything in a newspaper, magazine or online recently that stands out
as an important contribution to raising awareness about cancer and promoting informed
discussion about prevention, treatment, research or the challenges of living with the disease?
- Can you think of any journalist with a particularly good track record of writing about cancer?
If so, please nominate them for ESO’s 2013 Best Cancer Reporter Award, so we can acknowledge
their valuable work and encourage more quality media coverage of cancer.
You can read the article here. Nomination forms can be downloaded here.
|
|
|
Cancer World Newsletter - Centralising cancer services: is this the best way to improve results? |
|
|
|
|
Concentrating care of cancer patients in a few specialist centres ensures all patients are treated
by teams who specialise in treating certain cancers, and facilitates quality control. But it also
means many patients have to travel much further, which can be stressful if you are frail and unwell,
not to mention expensive. Are there better ways to improve outcomes? In this Crosstalk article
Renee Otter, former director of the Northern Comprehensive Cancer Centre in Groningen, The
Netherlands, argues that there are, while Susan O’Reilly, director of the Irish National Cancer
Control Programme disagrees.
What do you think?
|
|
|
Cancer World Newsletter - Cutting Edge |
|
|
|
We hit the spot: the new techniques that could bring interventional radiologists to the multidisciplinary table
Less invasive than surgery, less toxic than systemic therapies, interventional radiologists can deliver a growing variety of anti-cancer treatments isolated to local areas with a high degree of
accuracy. This Cuttinge Edge article outlines some of the latest techniques and asks: is it time to invite them to pull up a chair around the multidisciplinary table?
What do you think?
- Could many patients now treated surgically do just as well, or better, using interventiona lradiology?
- Should these techniques be used more widely in multimodality therapy, and if so how?
You can read the article here.
|
|
|
Cancer World Newsletter - Richard Sullivan: Why are we doing this? |
|
|
|
Is the "cosy little world of oncology" hampering efforts to control cancer by failing to apply the evidence-based criteria for policy making that it insists on for guiding clinical decisions?
That is the case made in this Cover Story by Richard Sullivan, professor of Cancer Policy and Global Health and leader of the recent Lancet Oncology Commission on Cancer Costs in High
-Income Countries. Sullivan argues that:
- The people with the loud voices who make the big decisions aren't necessarily the best qualified to do so
- Debate around affordability of cancer is being stifled because funders, governments,industry and other parts of the cancer community have become too tightly bound together
What do you think?
- Do we need a more open and rational process for making policy to ensure we get the best outcomes for the most patients?
You can read the article here.
|
|
|
International Women’s Day |
|
|
|
International Women's Day is an opportunity to sound the alarm about the danger of Lung Cancer for women. In Europe, cancer of the lung/bronchus is the third most common cancer among women. Lung cancer death has overtaken that of breast in Poland, the UK and Ireland. Lung cancer is deadly, yet it is highly preventable. A high percentage of lung cancer in women is smoking-related. About 1/3 of EU citizens smoke; in some EU countries up to 50% of women smoke. Annually, 650,000 Europeans die prematurely from smoking. Women and the public health community must be made aware that women are at risk of developing lung cancer. Effective smoking cessation programmes must be targeted at girls and young women.
For more information, please click here.
|
|
|
Cancer World Newsletter - Struck by cancer, killed by agesim |
|
|
|
|
A new survey has added to the considerable body of evidence showing that elderly people
get a worse deal from cancer services purely because of their age. In this editorial, Kathy
Redmond examines the extent of the problem, why it is happening, and the steps we must
urgently take to put an end to this deeply unfair discrimination.
What do you think?
|
|
|
3rd Balkan and Eastern European Masterclass in Clinical Oncology, 8-12 May 2013 - Dubrovnik, Croatia |
|
|
|
|
Chair: R. Popescu, CH/RO
Co-chair: S. Beslija, BA
The European School of Oncology is very glad to invite you to attend the “3rd Balkan andEastern European
Masterclass in Clinical Oncology” that will be held in Dubrovnik, Croatia, 08-12 May 2013.
ATTENDANCE TO THE MASTERCLASS IS BY APPLICATION ONLY
(Application deadline 3 MARCH 2013)
SUCCESSFUL APPLICANTS ARE GRANTED FREE REGISTRATION AND ACCOMMODATION
TEACHING FORMAT
The Masteclass offers plenary lectures regarding the state-of-the-art clinical evaluation and treatments
with reference to clinical guidelines and which conclude in taking-home messages. Furthermore, practical
training will be offered in the frame of clinical case presentations prepared and presented by the faculty
and participants for an interactive discussion. All participants will reside at the masterclass venue and
participation is compulsory throughout the course.
The Masterclass will be entirely in English and fluency in English is necessary for admission.
THE MASTERCLASS IS:
• A 3-day residential educational event
• Full immersion
• Clinically-oriented
• Multidisciplinary
• An international faculty of experts delivering lectures focusing on lung, GI and
breast cancers
ACCREDITATION
Application for CME recognition will be submitted to the Accreditation Council for Oncology in Europe (ACOE)
and to the European Society for Medical Oncology for the ESMO-MORA category 1 credits.
Further details can be found on the flyer that can be downloaded here or on the website
Roberta Ventura
Organising Secretariat
www.eso.net
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
|
|
SIOP Europe, the European Society for Paediatric Oncology (SIOPE), is delighted to present the latest version of its newsletter SIOPe News, bringing you new developments in paediatric cancer in Europe. Highlights in this edition include the 2013 International Childhood Cancer Awareness Day event at the European Parliament, the beginning of a new SIOPE presidency and the new SIOPE Board composition, the report from the SIOPE Annual General Assembly and the ENCCA General Assembly 2012, and the recent updates on the European Clinical Research Council (ECRC) for paediatric oncology.
Download the newsletter now
|
|
|
Cancer World Newsletter - Talking the isolation out of isolation |
|
|
|
|
How do you make life easier for leukaemia patients who have to spend weeks isolated
in a hospital room as they wait for a stem cell transplantation? This spotlight piece
looks at one novel idea, which has been trialled at a Dublin transplant centre, and is
helping patients retain a sense of connection with everyday life in the world outside.
What do you think?
|
|
|
|
